Serum podoplanin expression and frequency of thrombosis in adult de novo acute myeloid leukemia patients: An Egyptian single center study

Abstract

Background Cancer-associated thrombosis although represents a significant disease worse prognosis, understanding its underlying pathophysiology remains obscure. Podoplanin and its platelet ligand C-type lectin receptor type-2 have been investigated in the past few years for their potential role as procoagulant substances as it has been shown in many studies that binding of podoplanin with platelet C-type lectin receptor type-2 results in enhancement of platelet aggregation and thrombotic insults. Aim In this study, serum podoplanin was measured in newly diagnosed acute myeloid leukemia (AML) patients and its relation to the incidence of thrombosis in these patients in addition to its relation to other clinical, laboratory, and prognostic outcomes. Patients and methods This study included 80 participants (60 newly diagnosed adult AML patients and 20 age-matched and sex-matched healthy controls). Blood counts and flow cytometry using an acute leukemia panel were performed in addition to serum podoplanin, and cytogenetic studies including conventional karyotyping and fluorescence in-situ hybridization were performed to determine the risk group. The clinical status of the patients, particularly the incidence of thrombotic events in the following 6 months, as well as the D28 outcome and 6-month survival, were determined and reported. Results Serum podoplanin was highly expressed in AML patients compared with control samples, with a highly significant difference (P=0.001). There was a significant inverse relation between serum podoplanin level, hemoglobin level, and white blood cell count (P=0.006 and 0.036, respectively). Those with thrombotic events during the course of the disease did not show statistically significant results when compared with the control group with regard to serum podoplanin levels (P=0.546). Conclusion Serum podoplanin was much higher in AML patients than in the control group (P=0.000), and it was inversely related to platelet level (P=0.036) and total leukocyte count (P=0.006). However, there was no statistically significant link between podoplanin level and the incidence of thrombotic events (P=0.546).